🇺🇸 FDA

Company profile · Sponsor

Chongqing

Chongqing Claruvis Pharmaceutical Co.,

C34422A · NMPA pharma CN
Pipeline
2
Drugs
0
Patents
0

Quick answer

Chongqing (C34422A) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker C34422A
Exchange NMPA
Company type pharma
Headquarters CN

Pipeline (2)

Search pipeline →

  1. metronomic adjuvant chemotherapy with capecitabine

    Chongqing

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  2. Irinotecan liposome II combination therapy regimen

    Chongqing

    Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is Chongqing?

Chongqing (C34422A) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Chongqing sponsor?

We track 2 ClinicalTrials.gov-linked programs for Chongqing, including metronomic adjuvant chemotherapy with capecitabine and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Chongqing company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.